Salah H.
- Country
- The Netherlands
- Department
- Program Management
Research Overview
- Pharmacokinetic Evaluation of QRL-101 Formulations in Healthy Subjects for Amyotrophic Lateral Sclerosis (ALS)
- Phase 1 Study on Excretion Balance, Pharmacokinetics, and Metabolism of [14C] DC 806 in Healthy Male Subjects
- Phase I Double-Blind, Randomized, Placebo-Controlled Study on Safety, Tolerability, and Pharmacokinetics of THN391 in Healthy Volunteers
Data & Insights
Has run more than one trial at 1 of 3 partner sites.
Specializations
Neurological Research
The investigator conducts specialized research in neurodegenerative conditions, with particular emphasis on therapeutic interventions for severe neurological disorders.
- Amyotrophic Lateral Sclerosis (ALS)
- Alzheimer's Disease
Their work involves evaluating novel therapeutic compounds and their pharmacological properties in these conditions.
Autoimmune Studies
The investigator focuses on research involving autoimmune disorders, particularly examining innovative treatments for chronic inflammatory conditions.
- Lupus Erythematosus
- Lysosomal Storage Disorders
Their research encompasses evaluation of new therapeutic approaches for managing these complex autoimmune conditions.
Clinical Pharmacology
The investigator specializes in pharmacokinetic research and drug metabolism studies, with extensive experience in first-in-human trials.
- Drug Absorption and Metabolism
- Bioavailability Assessment
- Safety and Tolerability Studies
Their expertise extends to investigating novel compounds for various therapeutic applications including metabolic disorders and emergency medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.